Dr. Amanda D. Renaghan, MD

Dr. Renaghan practices at UVA University Medical Center in Charlottesville, Virginia.

Dr. Renaghan's NPI, 1770858847, was assigned on March 21, 2012. Dr. Renaghan graduated from University of Virginia School of Medicine in 2012. Dr. Renaghan holds Virginia license 0101262679.

Dr. Renaghan's primary practice is UVA University Medical Center, at 1215 Lee St, Charlottesville, VA 22908 in Charlottesville City. The practice phone is (434) 760-3439.

Dr. Renaghan's primary practice is UVA University Medical Center in Charlottesville, Virginia. Dr. Renaghan is also affiliated with University Medical Center. The medical group on file is UVA Physicians Group. Dmand AI also links Dr. Renaghan to 1 more hospital, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Renaghan practices, 4 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Renaghan's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Renaghan is licensed in Virginia.

CMS data shows 615 Medicare services from Dr. Renaghan across 10 procedure codes in 2024, for 240 Medicare patients. Medicare paid $44,341 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 240 Medicare patients who saw Dr. Renaghan in 2024. The largest group is 65 to 74, with 108 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 3.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Renaghan's median patient age at 67, with 46% women.

In 2024, Dr. Renaghan wrote 383 Medicare Part D claims for 67 patients. 89% of them were for generic drugs. CMS names the drug for 272 of them, across 11 drugs with 11 or more claims each, at $34,989 in total drug cost. In 2023, CMS named 180 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Renaghan for performance year 2024, reported as part of a group. Dr. Renaghan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Renaghan as offering telehealth.

Dmand AI links 12 papers to Dr. Renaghan, published from 2019 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Acute Kidney Injury, Immune Checkpoint Inhibitors and Renal Insufficiency, Chronic. Dr. Renaghan has published most often in Case Rep Nephrol Dial. Dr. Renaghan's most frequent co-authors are Ala Abudayyeh, MD, Arash Rashidi, MD and Meghan E. Sise, MD.

CMS Open Payments shows 3 general payments to Dr. Renaghan from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $312.

Dr. Renaghan graduated from University of Virginia School of Medicine in 2012.